Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab combination biomarker study in HER2-positive metastatic breast cancer
2014-001220-30Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer and HER2-positive breast cancer comparing Trastuzumab + lapatinib with Trastuzumab + chemotherapy (2 arms). Primary endpoint: Change in biomarker expression between pretreatment and progression biopsies. Started May 2014; status: terminated.
02
Drugs
trastuzumablapatinib
03
Conditions
breast cancerHER2-positive breast cancer
Beyond the preview
Go deeper on 2014-001220-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001220-30.